Petlife Investor Presentation

1. PetLife Pharmaceuticals, Inc. A NEW GENERATION IN VETERINARY MEDICINE Corporate Presentation October 2014 OTCQB: PTLF

2. Safe Harbor This document is being provided by PetLife solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document as constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and disclosure of information including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum and related documents, the only basis on which subscriptions may be made. Safe Harbor Statement Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by PetLife that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. The company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward- looking statements contained in this release. OTCQB: PTLF 2 © PetLife Pharmaceuticals, Inc. – All rights reserved

3. Snapshot (OTCQB: PTLF) Trading Statistics Price $0.85 Volume (3 month) 2,885 52 Week High/Low $1.57/$0.16 Total Shares Outstanding 58.0M Float 11.0M % Insiders 52% Market Cap $50M Other Headquarters Beverly Hills, CA Public Since August 12, 2014 Website www.PetLifepharma.com OTCQB: PTLF 3

4. About PetLife • PetLife Pharmaceuticals (PetLife) has developed and is launching a new generation of high-potency veterinary oncology medications & nutraceuticals • Escozine for Pets™ is based on the same patented formula of “Escozine” used for the treatment of cancer in humans but is amplified through polarization technology • Escozine for humans uses blue scorpion venom & is currently sold as either a nutraceutical or prescription drug in 40 countries, including the U.S. • Over 12 million dogs and cats are diagnosed with cancer annually. Our products will be utilized as both a preventative & treatment of cancer. OTCQB: PTLF 4 1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.

5. Large, Growing Addressable Market • Consumer spending on pets is ~$58 billion in 2014 and expected to grow 4%-6% annually • In 2013, $13+ billion was spent on over-the-counter medications for pets • Each year, 6.0M dogs and 6.5M cats are diagnosed with cancer in the U.S. • It’s estimated that ~10% of those diagnosed receive treatment • 90% of dogs & cats go untreated due to prohibitive costs and side effect of treatments Estimated 2014 Pet Sales within the U.S. ($ in billions) Food $4.7 $2.2 Supplies/OTC Medicine Vet Care $22.6 • Dogs and cats are ~35 times more likely to suffer from cancer than humans1 Live animal purchases $15.3 Pet Services: grooming & boarding OTCQB: PTLF 5 1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.

6. Why PetLife? • Tragically, 12.5 million pet owners who leave the vet’s office with a pet cancer diagnosis annually must decide: • Chemotherapy and/or surgery? • Escozine? • Or do nothing? • Our patented polarization technology allows us to amplify the potency of blue scorpion venom by +10x, allowing Escozine to: • Enhance binding preference to cancerous cells • Decrease the toxic side effects • Decrease cost of production • PetLife’s sister company, Medolife, has provided the worldwide rights to formulate, package and market a new product line, “Escozine for Pets™ OTCQB: PTLF 6 1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.

7. Medolife Sister Company Medolife invested $10 M over 10 years in Escozine for Humans Research and Development Medolife is dedicated to R&D of alternative natural products to effectively improve health at a cellular level. Escozine™ containing small molecular peptides (chlorotoxin “CLTX”) extracted from blue scorpion serum is an oncology therapy. Pre-clinical research demonstrates Escozine™ ability to kill cancer cells in animals (UCSD Moores Cancer Center, 2012) Markets Addressed Since 2007, Escozine™ for cancer prevention & treatment has been sold in 40 countries. High Quality Production Advanced production protocols to ensure the highest potency of Escozine™. Medolife has a first-of-its-kind scorpion reservation on the Caribbean island of Hispaniola, which is ideal habitat to support a healthy population of blue scorpions. Pet Centric Opportunity Humans, dogs and cats share similar histology. PetLife signed a worldwide license to Arthur Mikaelian’s IP and production patent # US 8097284 B2 and commenced operations. OTCQB: PTLF 7

8. PetLife – What is Escozine for Pets? Escozine for Pets is produced in US FDA-approved facility in Commerce, California. Clear liquid nutraceutical -- 2 versions for launch: Cancer Treatment & Prevention. Edibles to follow. Escozine contains “CLTX” peptide extracts from Blue Scorpion venom, harvested from scorpions at farms in the Caribbean where PetLife has significant production capacity. Patented polarization technology involves specific frequencies and harmonics, to achieve a resonance between the electromagnetic frequencies and the molecular frequency of the small molecular peptide “CLTX”. Polarized Dilute Blue Scorpion Venom solution leads to more apoptosis vs. non. See U.S. Patent 8,097,284 B2, as it pertains to Polarized Scorpion Venom solution, and the method for producing it. OTCQB: PTLF 8

9. Product Roadmap Concurrently, apply to US FDA in Q4-14 (ANDA) for approval of Rx strength versions for use by veterinarians: Introduce a line of Escozine for PetsTM preventative dog and cat treats, and an arthritis product, scheduled for introduction in Q1-15. Launch 1stproduct -- a nutraceutical version of Escozine for PetsTM– in Fall 2014. •IV administered •Injectable version for direct into tumors. Historically, the FDA process for similar types of pet products is straightforward and typically approved in 9 to 15 months. OTCQB: PTLF 9

10. Venom-Based Medication Gaining Traction & Government Support A Science Gaining Traction and Gov’t Support www.venomics-project.eu The VENOMICS consortium is composed of 8 partners representing 5 countries (France, Spain, Portugal, Belgium and Denmark), and is a mix of academic laboratories , SMEs and biotech firms devoted to novel drug discovery that aims at implementing a faster and more efficient strategy for the exploitation of venoms as a drug discovery resource. It has been assembled by VenomeTech, project leader, to select the best European experts in the fields of transcriptomics, proteomics, peptide production and drug discovery. _________________________________________________________________________ VENOMICS: “In the future, it can be envisaged that almost the full extent of the 40,000,000 biologically active molecules found in animal venoms will become available as a resource for drug discovery.” “This will offer a plethora of new opportunities in drug discovery and will permit the consortium to undertake in-house drug development and generate licensing opportunities for pharmaceutical companies in dire need of novel drug sources.” OTCQB: PTLF 10

11. Venomics in the News Bee, scorpion and snake venom may hold cancer cure By Jen Christensen,CNN updated 9:26 AM EDT, Tue August 12, 2014 (CNN) -- It's ancient medicine with a sci-fi-sounding twist. A scientist at the University of Illinois, Dipanjan Pan, and his team say they may have found a way to stop cancer cell growth, according to a paper presented at the American Chemical Society conference this week. The work is in very early stages, but has shown success in stopping breast cancer and melanoma cell growth in lab tests. Pan’s technique uses nanotechnology to deliver a synthesized element similar to the venom found in bees, snakes & scorpions. Alternative doctors in Cuba have used scorpion venom to fight brain tumors. Read the Full Article on CNN.com OTCQB: PTLF 11

12. Research Studies on Blue Scorpion Serum (an Active Ingredient in Escozine For Pets™) • UCSD Moores Cancer Center: Pre-clinical tests in 2012 demonstrated Escozine’s ability to target and kill malignant cells in animals as well as its synergy when used with traditional chemotherapy. • Cedars Sinai Medical Center & City of Hope, CA: Scientists demonstrated “Synthetic Version of Scorpion Venom Delivers Radioactive Iodine to Malignant Brain Tumors.” • Suez Canal University, Egypt: Cytotoxic and apoptotic effect of scorpion venom demonstrated in this study by Dr. Omran. • University of Alabama at Birmingham: Discovered chemical compounds in the scorpion's venom could be used to kill cancerous cells in brain without harming the healthy cells nearby. • Transmolecular received FDA approval that synthetic Chlorotoxin (CLTX) crosses blood-brain and tissue barriers & binds preferentially to glioma cells without affecting surrounding healthy tissue. Escozine’s natural CLTX - superior. • Seattle Children's Hospital: In conjunction with Prof. Fred Hutchinson at Cancer Research Center - Seattle has re-engineered the scorpion venom protein which binds to cancer cells, and is then joined with a fluorescent molecule "flashlight" to create a “tumor paint” to identify cancer cells. OTCQB: PTLF 12

13. Research Studies on Blue Scorpion Serum - II (an Active Ingredient in Escozine For Pets™) • Labiofam laboratory, Cuba: Study demonstrated that the Blue Scorpion venom causes cell death of malignant cells and is anti inflammatory and analgesic. • Labiofam laboratory, Cuba: Dr. Mikaelian participated in an open label human study with 8,302 patients commissioned by the Cuban pharmacological company, Labiofam. It demonstrated Blue Scorpion venom to be therapeutically effective ranging from improvement in quality of life to remission of malignant cancer cells across a broad spectrum of cancer types. • University of Washington: Scorpion venom with nanoparticles slows spread of brain cancer. • University of Massachusetts, Amherst: A study released suggests that anti-cancer chemotherapies which use (polarized) nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells. OTCQB: PTLF 13

14. Veterinary Testimonial Dr. Raul Jimenez - Biscayne Veterinary Center • Doctor of Veterinary Medicine (DVM) for 30 years. Education from Cornell, Auburn and University of Florida. • Principle of Biscayne Veterinary Center – Miami-based 24-hour veterinary hospital. Dr. Jimenez with dogs “Approximately eight months ago, my team started a medical trial treatment program for a group of 14 dogs and 3 cats diagnosed with cancer; adding the PetLife product after either tumoral surgical excision and/or oncology therapies. The outcome has been incredible. We have witnessed absolutely no negative side effects using this product with our patients. The results to date have ranged from: a.) completely slowing or halting the cancer’s progression b.) tumor reduction c.) systemic cancers in remission. The positive side effects have included: a.) all of the dogs and cats treated have regained a dramatically improved quality of life b.) an increase in their appetite c.) a dramatic improvement in both their energy level and mood. “I am pleased to wholeheartedly endorse PetLife as a product that should be used alone, and/or in conjunction with other clinical therapies for pets stricken with cancer. We plan to continue documenting our clinical data and to submit the results to our veterinary medical community.” OTCQB: PTLF 14

15. Customer Testimonials Geoff and Buddy • Golden Retriever • Small tumor called anal sac adenocarcinoma • Aggressive cancer, which is usually followed by chemo and radiation • Not a treatable cancer and surgery is only used as a band aid. • Like a gift from God, a friend told me about PetLife. • It's so easy! • Orally 3 times a day and because of his type of cancer, I also administer the solution as an enema a few times a week. • 6 months later, he is still acting happy and healthy!! • He's still acting like a puppy, and giving me lots of licks and love!!!! Thanks PetLife!!! Geoff Gita and Micky • Micky an American Eskimo, is 14 • Recently diagnosed with sarcoma • Huge growth on his shoulder, which causes so much hurt and pain • In pain and was fatigued all day long and couldn't move much • The vet advised me not to operate • There is no hope for my Micky to live that much longer • Within 10 days [of starting Escozine treatments] Mickey started having so much energy • The sparkle is back in his eyes, he has so much appetite now and looks like a happy Mickey Our family is so thankful to PetLife, Gita OTCQB: PTLF 15

16. Current Pet Chemo Choices Escozine For Pets is a category creating nutraceutical with no direct competition. Surgery carries its own risks. Chemotherapy treatment for dogs and cats with cancer is expensive and toxic -- with the same side effects: nausea, diarrhea, lost appetite, cachexia (‘wasting” loss of muscle and fat tissues) headache, hair loss, liver and kidney toxicity and susceptibility to opportune infections and more. Comparison of Escozine for Pets™ with Chemo Products Product Name Paccal/Kin a Vet- CA1™ 2 Palladia™ Escozine for Pets™ Years In the Market 5 7 Toxicity Level --10 --10 0 0-10* Efficacy Level Vet chemo treatments fall into two categories: • Off-label use of human oncology products • Specifically registered drugs for veterinary oncology: o Palladia – Pfizer/Zoetis. First pet specific chemo drug o Paccal/Kina Vet-CA1 - Oasmia Pharmaceutical AB, Uppsala Sweden -- “Conditionally approved” 7 4 8 0-10* Supportive Medication required to control side effects --10 --10 0 0-10* Cost of the Product --4 --7 --3 The full effectiveness of Paccal Vet®-CA1 has yet to be demonstrated to the FDA. It has been prevented from entering the market in certain countries because of high toxicity and severe side effects. 0-10* Patent* $507 10 $975 10 $358 10 0=No 10= Yes FDA 10 10 0  The cost to simply receive diagnosis is $200-$500  Chemotherapy , depending on type and stage of cancer, ranges $2,000 to $10,000  Requires a tremendous time commitment from owner  Takes a major toll on the quality of the pet’s life  Standard of care has a success rate ~ 40% Registration* 0=No 10= Yes Total Score 5 1 28 Scale: --10 to +10 OTCQB: PTLF 16

17. Brand Strategy & Roadmap Launch Escozine for Pets™ Aggressive multi-channel marketing strategy FDA clinical trials for Rx products Build intellectual property portfolio & leverage portfolio to introduce new products Evaluate for use in U.S. livestock market, which suffers from high rates of cancer Expand internationally (i.e. China, UK, Canada & Brazil) OTCQB: PTLF 17

18. PetLife Marketing Plan – Multi-Channel Online • Implement an aggressive direct-to-consumer online marketing campaign to drive US and select International sales. Utilize integrated SEO, Facebook, & Banner Ad Campaign to target pet owners and thought leaders Retail • Market to distributors and brick & mortar outlets such as PetSmart and Petco Veterinarians • Utilize specialized, vertical marketing firm to both educate and sell to the vet market Multi-level Marketing • Partnered with a proven multi-level marketing (MLM) platform to drive affiliate sales • MLM partner will utilize an initial sales and marketing force of 100 people Direct Response: Infomercials • Retail sales driven by infomercials range from 2 to 15 times the infomercial sales • Partner with well-known celebrity, well-respected veterinarian, to film differentiated 2 to 30 minute infomercials on Escozine for Pets™ Promotion • Direct to vet, direct to consumer, direct to wholesaler • Trade shows, direct vet outreach and online webinars Media • Engage industry relevant PR firm to generate media coverage for products in general news, family, pet and veterinarian publications, e-zines, videos and the blogosphere to communicate Escozine for Pets™ features and benefits • OTCQB: PTLF 18

19. PetLife Financial Model Revenue opportunity = % of market penetration • Revenue sources: Preventative, cancer & post-cancer therapy products and, if successful, FDA approved Rx products. • Assumes multiple pets and growing % of recurring (auto-ship) purchases  Gross Margins targeted above 70% with ASP to customer of $356 per month  FDA clinical trial expenses forecasted at $8 - $10 million total for both Rx products ~12.5 million dogs & cats diagnosed with cancer annually: owners must make a decision  0.25% market penetration = $133 million revenue  0.5% market penetration = $266 million revenue Palladia is 1stPet-Specific FDA approved Oncology Product  Palladia (chemo) approved 2009 - dogs only  Spent ~$15 million clearing FDA. (Today, est. cost is $8M - $10M)  Year One: spent ~$1M on marketing  generated ~$150M in sales OTCQB: PTLF 19

20. PetLife Management Arthur G. Mikaelian, Ph.D., Founder, CEO and President • Invented patented Polarization technology • Researching stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. • Ph.D. Biological Psychology - Vernadsky University of Biosphere Knowledge, Moscow Bruce Niswander, Chief Financial Officer • 30 years commercializing new, entrepreneurial ventures • MBA and JD from Ohio State University • Certified Financial Analyst (CFA) Vivek Ramana, Chief Medical Officer • Prior, Ambit Biosciences Senior Safety Medical Officer/Senior Medical Director Previously, AdPharma CMO & President • Former Medical Director, R&D for Pharmaceutical Clinical Research, JVs BMS, Pfizer, Schering Plough, Astra Zeneca • Post-Doctoral Studies in Clinical Pharma, Drug R&D and Regulation from TUFTS University in Boston Strategic partners Samson Pharmaceuticals, Commerce, CA – US FDA approved facility, manufactures PetLife products. Aguas Vivas Laboratory, Santo Domingo, DR – Venom extraction and compound preparation OTCQB: PTLF 20

21. Investment Summary Multi-channel market strategy: Direct, PR, retail, vet clinics, infomercial, affiliate sales PetLife to Launch Escozine for PetsTM nutraceutical in Fall 2014 US: Over 12 million cats and dogs are diagnosed with cancer each year US $13 billion TAM for OTC vet meds. Total US 2014 pet spend=$58B Breakthrough science with new therapy. Currently vets use toxic human chemo drugs, scaled by pets’ weight Highly Experienced Industry Management and R&D Team (Medolife) Highly Scalable business with targeted Gross margins of 70%+ OTCQB: PTLF 21 1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.

22. Contact PetLife Pharmaceuticals, Inc. 433 N. Camden Dr. Beverly Hills, CA 90210 T: (310) 279-5152 www.PetLifePharma.com Sebastian Serrell-Watts Co-founder, Executive Vice President E: info@petlifepharma.com Investor Relations: MZ Group Greg Falesnik, Senior Vice President T: (949) 385-6449 E: greg.falesnik@mzgroup.us OTCQB: PTLF 22